Current approaches in the management of low risk Hodgkin lymphoma in children and adolescents Review uri icon


MeSH Major

  • Hodgkin Disease


  • The outcome for children and adolescents with low risk Hodgkin lymphoma (HL) is excellent, with event-free survival >85% and overall survival >95%. Historically, however, treatment has come at the cost of significant long-term toxicity from chemotherapy, radiation or a combination of these. Recent treatment strategies have focused on maintaining high event-free and overall survival while minimizing the use of therapy associated with late effects. The strategies used to achieve this vary greatly among paediatric cooperative groups and there is no one standard treatment for children with low risk HL. This review summaries recent clinical trials in paediatric low risk HL and addresses some of the important considerations when comparing trials, including differences in the definition of low risk HL, differences in outcome among histological subtypes and varying approaches to reduce or eliminate radiation therapy. Recommendations are provided for the treatment of children with low risk HL outside the setting of a clinical trial.

publication date

  • January 2015



  • Review



  • eng

Digital Object Identifier (DOI)

  • 10.1111/bjh.13372

PubMed ID

  • 25824371

Additional Document Info

start page

  • 647

end page

  • 60


  • 169


  • 5